Molecular status 36 months after TKI discontinuation in CML is highly predictive for subsequent loss of MMR-final report from AFTER-SKI
Authors | |
---|---|
Year of publication | 2021 |
Type | Article in Periodical |
Magazine / Source | Leukemia |
MU Faculty or unit | |
Citation | |
Web | https://www.nature.com/articles/s41375-021-01173-w.pdf |
Doi | http://dx.doi.org/10.1038/s41375-021-01173-w |
Keywords | TKI discontinuation; CML; MMR-final report; AFTER-SKI |
Description | Discontinuation of tyrosine kinase inhibitor (TKI) treatment for chronic phase (CP) CML patients with a deep molecular response (DMR) has entered standard practice. This is based on numerous clinical studies showing that ~50% of patients with DMR can stop TKI treatment without imminent disease relapse. However, in most of these trials long-term follow-up has been limited. |